Full Value Proposition

The Full Value Proposition, also known as the comprehensive assessment of Influenza Vaccine Value (IVA), encompasses an inclusive approach to understanding the true benefits of vaccines. This project, supported by the World Health Organization (WHO), aims to generate valuable data and information for various stakeholders. Traditionally, the value of vaccines has been measured solely in terms of the number of cases they prevent and the associated cost savings. However, the full value proposition acknowledges a broader scope, encompassing the prevention of not only flu but also other diseases like cardiovascular disease and COPD, as well as the overall societal impact and cost savings they generate.

The goal of the Full Value Proposition is to explore the complete value of vaccines, considering their impact on society, economics, and disease reduction. This project comprises a series of activities, organized sequentially, with three main focus areas. Notably, it primarily seeks to understand the value of next-generation influenza vaccines. While some data will be collected on the current vaccines, the main emphasis lies in comprehending the potential value of improved vaccines, whether through increased efficacy or longer-lasting protection.
The first component of this initiative involves analyzing the vaccine landscape and monitoring the development of next-generation vaccines. By tracking these advancements, the project aims to determine the likelihood of obtaining vaccines that are more effective, longer-lasting, or offer broader protection. This landscaping activity provides valuable insights into the future of influenza vaccines.

The second focus area revolves around understanding vaccine supply, both present and future, along with the corresponding demand curves. To truly assess the value of next-generation vaccines, it is crucial to gauge their utilization. By estimating the demand for these vaccines over several years and examining the potential vaccine coverage, a clearer understanding of their true value can be achieved.

The third component involves consolidating all the gathered information and constructing cost-benefit models. These models evaluate the potential disease prevention and associated costs that could be achieved through the utilization of improved vaccines. By bringing together all the relevant data, this step provides a comprehensive assessment of the overall value of next-generation vaccines.

The project is currently ongoing, with an expected completion date at the end of 2024. It is conducted in collaboration with the Centers for Disease Control and Prevention (CDC) to ensure a comprehensive approach that also focuses on maximizing the use and understanding of the full impact of the current vaccines. While the WHO primarily focuses on the next generation of vaccines, they acknowledge the importance of optimizing the utilization of existing vaccines until the improved versions become available.